Fig. 5: The combined inhibition of BCL-2 and MCL-1 is significantly more effective in AML cells and AML stem/progenitor cells from patients with TP53 mutations. | Blood Cancer Journal

Fig. 5: The combined inhibition of BCL-2 and MCL-1 is significantly more effective in AML cells and AML stem/progenitor cells from patients with TP53 mutations.

From: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Fig. 5

A, B AML patient samples (n = 8) with TP53 mutations were treated with VEN, AMG176, or both for 48 h. Apoptosis (A) and viable cells (B) were determined by flow cytometry. h hour. Error bars represent mean ± SEM of data from individual patients. C AML patient samples (n = 8) with TP53 mutations were treated with various concentrations of VEN, AMG176, or both for 48 h. Apoptosis and the CI values from two representative patient samples (#26, #28) are shown. Cell death is expressed as specific apoptosis and viable cells are expressed as % compared to the control of 100%. con control.

Back to article page